News articles about NuVasive (NASDAQ:NUVA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 46.5881133165293 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Form 3 NUVASIVE INC For: Aug 01 (streetinsider.com)
- Form 3 NUVASIVE INC For: Aug 01 - StreetInsider.com (streetinsider.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NuVasive Inc. (NUVA) - PR Newswire (press release) (prnewswire.com)
- Peter Michael Leddy Buys 7,850 Shares of NuVasive, Inc. (NUVA) Stock (americanbankingnews.com)
- NuVasive, Inc. (NUVA) Becomes Oversold as a consequence of the RSI 22.16 fact - Voice Of Analysts (analystsbuzz.com)
Several brokerages have recently weighed in on NUVA. Jefferies Group LLC reissued a “buy” rating and issued a $84.00 price objective on shares of NuVasive in a research report on Friday, June 30th. Cowen and Company reissued an “outperform” rating and issued a $85.00 price objective on shares of NuVasive in a research report on Monday, May 15th. Royal Bank Of Canada reissued a “buy” rating and issued a $85.00 price objective on shares of NuVasive in a research report on Thursday, July 20th. TheStreet raised shares of NuVasive from a “c+” rating to a “b” rating in a research report on Wednesday, May 3rd. Finally, Zacks Investment Research raised shares of NuVasive from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. NuVasive currently has an average rating of “Buy” and a consensus price target of $81.18.
NuVasive (NASDAQ:NUVA) traded up 3.51% during trading on Friday, hitting $65.79. 1,312,207 shares of the company traded hands. The stock has a 50 day moving average price of $76.85 and a 200 day moving average price of $74.43. NuVasive has a 12-month low of $56.70 and a 12-month high of $81.68. The company has a market capitalization of $3.34 billion, a P/E ratio of 106.11 and a beta of 1.06.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The business had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. During the same period in the previous year, the business posted $0.40 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities analysts anticipate that NuVasive will post $2.00 earnings per share for the current year.
In other news, EVP Peter Michael Leddy acquired 7,850 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were acquired at an average cost of $63.88 per share, for a total transaction of $501,458.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect NuVasive (NASDAQ:NUVA) Share Price” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2017/08/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-nuvasive-nasdaqnuva-share-price.html.
About NuVasive
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
